CellApr 24, 2026

Finding antidepressant drug targets by studying how specific cell receptors work

Psychedelic Science Weekly Brief ↗PubMed ↗DOI ↗

Updated Jun 27, 2026

Abstract

Essence

Ketamine-linked circuit mechanisms pointed to mPFC somatostatin-interneuron GPCR targets with antidepressant-like effects in preclinical models.

Evidence

Mechanistic preclinical study combined ketamine experiments, chronic-stress circuit analysis, RNA sequencing of mPFC SstIN-enriched GPCRs, and target validation for antidepressant-like responses.

Caveat

The therapeutic claims come from molecular, circuit, and behavioral preclinical experiments, so human efficacy and side-effect reduction remain untested.

Simplified

Depression is driven by dysfunction in discrete neural circuits, but a deeper understanding of the underlying molecular and synaptic mechanisms is needed to guide the development of therapeutics. Here, we decipher the mechanisms of action of the fast-acting antidepressant ketamine to enable the identification of G protein-coupled receptor (GPCR) antidepressant targets. We find that the behavioral effects of ketamine rely on mu-opioid receptors (MORs), which are enriched in somatostatin-expressing interneurons (SstINs) in the medial prefrontal cortex (mPFC). Chronic stress drives presynaptic hypertrophy of mPFC SstINs and excessive inhibition of pyramidal neurons, which is rescued by ketamine. Motivated by these findings, we use RNA sequencing to identify mPFC SstIN-enriched GPCRs and validate the antidepressant potential of promising targets. Synergistic targeting of multiple GPCRs enables potent antidepressant-like responses with reduced side effects. Together, these findings reveal a general approach to identifying therapeutic GPCR targets for brain disorders. + + +